Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Second generation version of MK-869: Phase II

Merck said it is in Phase II dose-finding studies with

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE